Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-813160 + gemcitabine + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous
01
Overview
BMS-813160 + gemcitabine + nab-paclitaxel is an investigational combination therapy studied primarily for pancreatic ductal adenocarcinoma and other advanced solid tumors. **BMS-813160** is a small molecule oral antagonist targeting both C-C chemokine receptor type 2 (CCR2) and type 5 (CCR5), which modulate tumor-associated macrophages and are implicated in the tumor microenvironment. **Gemcitabine** is a nucleoside analog used as standard chemotherapy, and **nab-paclitaxel** (albumin-bound paclitaxel) is a microtubule inhibitor chemotherapeutic. The combination aims to both attack tumor cells directly (via chemotherapy) and modulate the immune microenvironment (via CCR2/CCR5 blockade) to enhance antitumor immunity. This regimen has primarily been evaluated in phase 1/2 trials for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma[2][1][4].
- Other names
- nab-paclitaxelgemcitabineBMS-813160BMS813160BMS 813160
02
Targets
CCR2 (Chemokine (C-C motif) Receptor 2)CCR5 (C-C chemokine receptor type 5)DNA polymerase familyRNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on BMS-813160 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-813160 + gemcitabine + nab-paclitaxel.